Lipegfilgrastim
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lipegfilgrastim
- Lipegfilgrastim: From G-CSF-Based Neutrophil Support to Primary Release Disorder of Platelets
Lipegfilgrastim: From G-CSF-Based Neutrophil Support to Primary Release Disorder of Platelets
One-Sentence Summary
Lipegfilgrastim’s specific original approved indication is not documented in this dataset, but available data describe it as a PEGylated G-CSF (granulocyte colony-stimulating factor) analog that stimulates neutrophil precursor proliferation. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, with a prediction score of 99.93%, but this candidate ranks only 1,043rd overall and is currently backed by 0 clinical trials and 0 publications. The drug is also not marketed in Taiwan (0 TFDA licenses), and key safety and MOA fields are flagged as data gaps.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in dataset (drug class: G-CSF analog, per mechanism-of-action text) |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.93% (global rank 1,043) |
| Evidence Level | L5 (model prediction only) |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of TFDA Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Lipegfilgrastim is flagged as a data gap (DG002) in the structured original_moa field. However, the evidence pack’s mechanistic rationale text describes Lipegfilgrastim as a PEGylated G-CSF analog that acts on the G-CSF receptor to stimulate proliferation and differentiation of granulocyte (neutrophil) precursor cells — a pathway centered on myeloid/neutrophil generation in the bone marrow.
Primary release disorder of platelets is a defect in platelet granule secretion/activation signaling, a biologically distinct pathway from neutrophil colony stimulation. The evidence pack itself explicitly flags this gap, stating there is “no known overlap” between G-CSF receptor signaling and platelet granule release, and characterizes the mechanistic link as weak and purely data-driven (i.e., an artifact of knowledge-graph proximity between “hematopoietic growth factor” concepts rather than a validated shared pathway).
In short: this is a case where the TxGNN score is high, but the model’s own accompanying rationale does not support a plausible mechanistic bridge between the original G-CSF pharmacology and the predicted platelet-disorder indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
(Note: a broader evidence sweep across all 10 predicted indications for this drug found only one trial record, NCT03744676, associated with rank 9 “Scott syndrome” — but it involves an unrelated drug (lisocabtagene maraleucel, a CAR-T therapy) and an unrelated condition (B-cell non-Hodgkin lymphoma), and was judged a database mismatch, not genuine supporting evidence.)
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Lipegfilgrastim currently holds no TFDA marketing authorization (0 licenses on file); market status is recorded as not marketed in Taiwan. No product name, dosage form, or approved-indication text is available to report.
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug-interaction data were all queried but returned no results — DDI query status: not_found; warnings/contraindications: data gap DG001, classified as Blocking severity, since it prevents initial safety screening (S1 stage).)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction is supported by evidence level L5 only (AI prediction with no corroborating trials or literature), and the model’s own mechanistic rationale describes the drug–disease link as weak and non-overlapping. Combined with the drug having no Taiwan marketing authorization and a blocking safety data gap, this candidate does not meet the threshold to advance past S0.
To proceed, the following is needed:
- TFDA-equivalent product labeling (warnings/contraindications) to clear the blocking data gap (DG001) before any S1 safety screening
- Confirmed mechanism-of-action documentation and original indication record for Lipegfilgrastim (DG002)
- Preclinical or mechanistic studies directly testing G-CSF receptor signaling’s role (if any) in platelet granule release disorders
- At minimum one registered clinical trial or case report directly evaluating Lipegfilgrastim in a platelet release/secretion disorder before re-scoring evidence level above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.